


Tipifarnib

Cat. No.:	HY-10502		
CAS No.:	192185-72-1		
Molecular Formula:	C ₂₇ H ₂₂ Cl ₂ N ₄ O		
Molecular Weight:	489.40		
Target:	Farnesyl Transferase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (68.10 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.0433 mL	10.2167 mL	20.4334 mL
	5 mM	0.4087 mL	2.0433 mL	4.0867 mL
	10 mM	0.2043 mL	1.0217 mL	2.0433 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 20% HP-β-CD/10 mM Citrate pH 2.0
Solubility: 10 mg/mL (20.43 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Tipifarnib (IND 58359) binds to and inhibits farnesyltransferase (FTase) with an IC₅₀ of 0.86 nM. Antineoplastic activity and antiparasitic activity^[1].

IC₅₀ & Target

IC₅₀: 0.86 nM (FTase)

<p>In Vitro</p>	<p>Tipifarnib is a potent inhibitor of Trypanosoma Cruzi with the ED₅₀ of 4 nM^[1]. Tipifarnib inhibits isolated human farnesyltransferase for a lamin B peptide and for the K-RasB peptide with IC₅₀ of 0.86 nM and 7.9 nM, respectively^[2]. Tipifarnib shows inhibition of cell growth or angiogenesis, and induction of apoptosis in aggressive prostate cancer (PCa)^[3]. Tipifarnib (0.25 μM, 1 μM; 48 h) shows a significant decrease in the concentration of exosomes in C4-2B cells and PC-3 cells^[3].</p> <p>Tipifarnib (1 μM) significantly inhibits the protein concentration of Alix, nSMase2, and Rab27a in C4-2B cells^[3]. Tipifarnib (0.25 μM) significantly inhibits the activation of p-ERK (downstream effector molecule of the Ras/Raf/ERK signaling pathway) but not total ERK in C4-2B and PC-3 cells^[3]. Tipifarnib (1.25-5 μM; 30 min) promotes endoplasmic reticulum stress in U937 cells, resulting in dysregulation of intracellular calcium homeostasis^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
<p>In Vivo</p>	<p>Tipifarnib (10 mg/kg; ip; single dose) upregulated antiapoptotic protein, Bcl-xL in liver, and prevents mouse death induced by GalN/LPS^[5]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="347 688 1515 957"> <tr> <td>Animal Model:</td> <td>GalN/LPS challenge mouse^[5]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg; while challenge with GalN (400 mg/kg; IP) and LPS (32 g/kg)</td> </tr> <tr> <td>Administration:</td> <td>IP; 60 min before challenge</td> </tr> <tr> <td>Result:</td> <td>Protected primary hepatocytes from GalN/tumor necrosis factor-induced cell death. Inhibited caspase 3 activation and upregulating antiapoptotic proteins.</td> </tr> </table>	Animal Model:	GalN/LPS challenge mouse ^[5]	Dosage:	10 mg/kg; while challenge with GalN (400 mg/kg; IP) and LPS (32 g/kg)	Administration:	IP; 60 min before challenge	Result:	Protected primary hepatocytes from GalN/tumor necrosis factor-induced cell death. Inhibited caspase 3 activation and upregulating antiapoptotic proteins.
Animal Model:	GalN/LPS challenge mouse ^[5]								
Dosage:	10 mg/kg; while challenge with GalN (400 mg/kg; IP) and LPS (32 g/kg)								
Administration:	IP; 60 min before challenge								
Result:	Protected primary hepatocytes from GalN/tumor necrosis factor-induced cell death. Inhibited caspase 3 activation and upregulating antiapoptotic proteins.								

CUSTOMER VALIDATION

- Circ Res. 2024 Jun 7.
- Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.
- Mol Cell. 2021 Oct 7;81(19):4076-4090.e8.
- J Immunother Cancer. 2022 Apr;10(4):e004399.
- Br J Cancer. 2024 Jan 26.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Devendra S Puntambekar, et al. Inhibition of farnesyltransferase: a rational approach to treat cancer? J Enzyme Inhib Med Chem. 2007 Apr;22(2):127-40.
- [2]. End DW, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001 Jan 1;61(1):131-7
- [3]. Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA